Pure red cell aplasia occurring during ibrutinib therapy for chronic lymphocytic leukemia.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners(2023)
Abstract
Our case demonstrates a need to evaluate the risk of developing AIC before initiating ibrutinib. For patients with high-risk factors for AIC episodes, the transient addition of other immunosuppressive therapies should be taken into consideration.
MoreTranslated text
Key words
Chronic lymphocytic leukemia, pure red cell aplasia, ibrutinib
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined